Howdy everyone, Merck are shovelling funds at immutep for combo trials with its star product Pembro and Immuteps only EFTI... we all know that... OK, another thing we all know is that Mercks pembro(keytruda) is approaching end of patent scenario within a couple of years till all the copycats come up with an alternative product that will effect Mercks bottom line... Alright, enough drivel, but also of interest , 6 months ago Merck was trading at $102USD, today it's at $75USD... Mercks continued interest in Immutep leads me to think Merck may be interested in the fact that immuteps product "EFTI" has a patent expiry date of 2036 which in combo with keytruda could lead to a process called "evergreening" in which Merck could get an extension of it's patent until 2036 but only in combination with "EFTI"... OK again, the Head and neck cancer combo whilst promising is not a blockbuster, but believe me the lung cancer combo certainly has the potential to be.... Merck need a replacement for Keytruda, can Immutep help in that regard?..We will see..
IMM Price at posting:
29.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)